Peripheral neuropathy during Infliximab therapy: a case study

• Published in: The Pan African medical journal 2016, Vol.24, p.271-271
• Main Authors: Zinebi, Ali, Akhouad, Youssef, Rkiouak, Adil, Reggad, Ahmed, Kasmy, Zohour, Boudlal, Mostafa, Rabhi, Monsef, Ennibi, Khalid, Chaari, Jilali
• Format: Article
• Language: fre
• Subjects: Dose-Response Relationship, Drug; Female; Gastrointestinal Agents - administration & dosage; Gastrointestinal Agents - adverse effects; Humans; Infliximab - administration & dosage; Infliximab - adverse effects; Middle Aged; Peripheral Nervous System Diseases - chemically induced; Proctocolitis - drug therapy; Time Factors; Tumor Necrosis Factor-alpha - antagonists & inhibitors
• ISSN: 1937-8688
• DOI: 10.11604/pamj.2016.24.271.3498

Anti TNF alpha treatments are wide spectrum therapies. Multiple side effects have been reported in recent years, particularly peripheral neuropathies. We report a case of axonal neuropathy occurring three months after starting treatment with Infliximab. Our study focused on a 60-year old female patient treated for therapy-resistant hemorrhagic rectocolitis, requiring treatment with infliximab. Three months later, the patient had sensory axonal neuropathy. Etiologic assessment remained negative and dose reduction was accompanied by an improvement in symptoms. The time between initiation of treatment with Infliximab and the onset of clinical manifestations as well as improvement after dose reduction advocate the responsibility of infliximab in the occurrence of sensory neuropathy. Its management is not standardized and should be discussed case by case.